ALEMBIC PHARMA | CIPLA | ALEMBIC PHARMA/ CIPLA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 19.4 | 35.9 | 54.2% | View Chart |
P/BV | x | 7.5 | 4.2 | 180.3% | View Chart |
Dividend Yield | % | 0.5 | 0.5 | 103.4% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC PHARMA Mar-19 |
CIPLA Mar-20 |
ALEMBIC PHARMA/ CIPLA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 664 | 586 | 113.4% | |
Low | Rs | 412 | 357 | 115.6% | |
Sales per share (Unadj.) | Rs | 208.7 | 207.0 | 100.8% | |
Earnings per share (Unadj.) | Rs | 31.0 | 18.6 | 166.7% | |
Cash flow per share (Unadj.) | Rs | 37.1 | 33.2 | 111.9% | |
Dividends per share (Unadj.) | Rs | 5.50 | 4.00 | 137.5% | |
Dividend yield (eoy) | % | 1.0 | 0.8 | 120.4% | |
Book value per share (Unadj.) | Rs | 144.2 | 195.5 | 73.8% | |
Shares outstanding (eoy) | m | 188.52 | 806.35 | 23.4% | |
Bonus/Rights/Conversions | - | ESOS | - | ||
Price / Sales ratio | x | 2.6 | 2.3 | 113.3% | |
Avg P/E ratio | x | 17.4 | 25.3 | 68.5% | |
P/CF ratio (eoy) | x | 14.5 | 14.2 | 102.1% | |
Price / Book Value ratio | x | 3.7 | 2.4 | 154.8% | |
Dividend payout | % | 17.7 | 21.5 | 82.5% | |
Avg Mkt Cap | Rs m | 101,461 | 379,912 | 26.7% | |
No. of employees | `000 | NA | 25.8 | 0.0% | |
Total wages/salary | Rs m | 7,467 | 30,270 | 24.7% | |
Avg. sales/employee | Rs Th | NM | 6,459.6 | - | |
Avg. wages/employee | Rs Th | NM | 1,171.2 | - | |
Avg. net profit/employee | Rs Th | NM | 580.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 39,347 | 166,949 | 23.6% | |
Other income | Rs m | 94 | 3,442 | 2.7% | |
Total revenues | Rs m | 39,441 | 170,391 | 23.1% | |
Gross profit | Rs m | 8,736 | 32,060 | 27.2% | |
Depreciation | Rs m | 1,152 | 11,747 | 9.8% | |
Interest | Rs m | 184 | 1,974 | 9.3% | |
Profit before tax | Rs m | 7,493 | 21,782 | 34.4% | |
Minority Interest | Rs m | 11 | -475 | -2.3% | |
Prior Period Items | Rs m | -93 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,568 | 6,312 | 24.8% | |
Profit after tax | Rs m | 5,844 | 14,995 | 39.0% | |
Gross profit margin | % | 22.2 | 19.2 | 115.6% | |
Effective tax rate | % | 20.9 | 29.0 | 72.2% | |
Net profit margin | % | 14.9 | 9.0 | 165.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,577 | 117,038 | 16.7% | |
Current liabilities | Rs m | 14,896 | 43,931 | 33.9% | |
Net working cap to sales | % | 11.9 | 43.8 | 27.2% | |
Current ratio | x | 1.3 | 2.7 | 49.3% | |
Inventory Days | Days | 90 | 96 | 93.8% | |
Debtors Days | Days | 45 | 85 | 53.3% | |
Net fixed assets | Rs m | 27,097 | 107,424 | 25.2% | |
Share capital | Rs m | 377 | 1,613 | 23.4% | |
"Free" reserves | Rs m | 26,811 | 156,018 | 17.2% | |
Net worth | Rs m | 27,188 | 157,630 | 17.2% | |
Long term debt | Rs m | 4,993 | 23,693 | 21.1% | |
Total assets | Rs m | 47,778 | 236,626 | 20.2% | |
Interest coverage | x | 41.7 | 12.0 | 346.5% | |
Debt to equity ratio | x | 0.2 | 0.2 | 122.2% | |
Sales to assets ratio | x | 0.8 | 0.7 | 116.7% | |
Return on assets | % | 12.6 | 7.2 | 175.9% | |
Return on equity | % | 21.5 | 9.5 | 225.9% | |
Return on capital | % | 23.6 | 12.8 | 183.8% | |
Exports to sales | % | 0 | 33.0 | 0.0% | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | 55,175 | 0.0% | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 19,453 | 56,036 | 34.7% | |
Fx outflow | Rs m | 6,065 | 6,764 | 89.7% | |
Net fx | Rs m | 13,388 | 49,272 | 27.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,120 | 30,685 | 26.5% | |
From Investments | Rs m | -7,556 | 1,040 | -726.3% | |
From Financial Activity | Rs m | 590 | -29,488 | -2.0% | |
Net Cashflow | Rs m | 1,153 | 2,340 | 49.3% |
Indian Promoters | % | 74.1 | 16.0 | 463.1% | |
Foreign collaborators | % | 0.0 | 20.8 | - | |
Indian inst/Mut Fund | % | 2.9 | 12.2 | 23.8% | |
FIIs | % | 9.1 | 23.7 | 38.4% | |
ADR/GDR | % | 0.0 | 1.1 | - | |
Free float | % | 13.9 | 26.2 | 53.1% | |
Shareholders | 49,328 | 161,166 | 30.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC PHARMA With: GSK PHARMA JUBILANT LIFE SCIENCES DIVIS LABORATORIES PIRAMAL ENTERPRISES NATCO PHARMA
Compare ALEMBIC PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Asian share markets and US stock futures are trading higher today as investors awaited comments from Joe Biden's Treasury Secretary nominee Janet Yellen on US stimulus and the dollar.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More